Attempts to curtail prior authorizations for patients insured by Medicare Advantage plans have failed in back-to-back legislative sessions in 2019 and 2021, but a new bill has some experts hopeful that the third time is a charm.
“The previous bill had a $16 billion price tag from the Congressional Budget Office,” Robert W. Levin, MD, past president of the Florida Society of Rheumatology, president of the Alliance for Transparent and Affordable Prescriptions, and associate affiliate professor of medicine at the University of South Florida, told Healio. “The way the new bill is